Join us for a discussion on the opportunities and challenges of funding and licensing for biopharma in APAC, and how biotech companies can take advantage of the favorable market conditions in this region to bring their innovations through development and to market – in APAC and around the world.
Presented in APAC time zones 8:30am IST (India), 10am CST (China), 11am JST (Japan) and KST (Korea), 1pm ADST (Australia)
The biopharmaceutical industry is rapidly expanding all over the world. Traditional markets such as the United States and Europe continue to lead much of the industry, but it is becoming impossible to ignore the explosive growth in the Asia and Pacific (APAC) region, driven largely by countries like China, India and Japan. While venture capital investment may have slowed overall in the face of the pandemic, this was not so in APAC. In Chinese biotech alone, for example, the first half of 2020 saw 95 biotech deals, worth $12 billion, an unprecedented amount of activity.
These markets offer various unique advantages for investors: some have strong areas of expertise that are ripe for investment, such as animal health in Australia, while others offer unique opportunities like the accelerated regulatory environment in China. APAC has increasingly drawn interest from investors and multinationals, and is seen to be a significant source of innovation. There is no question that all eyes are on APAC as a potential opportunity for placing bets.
In this webinar, Syneos Health will lead a discussion on the opportunities and challenges of funding and licensing for biopharma in APAC, and how biotech companies can take advantage of the favorable market conditions in this region to bring their innovations through development and to market – in APAC and around the world.
- LEARN how to mitigate the challenges faced by APAC biotechs seeking to gain access to US/EU investors and partners.
- UNDERSTAND how to maximize potential interest from outside investors in APAC markets.
- DISCUSS how to strengthen the case for valuation and market potential of your asset.
Neel Patel, Executive Managing Director and Head, Commercial Advisory Group
Neel Patel brings to Syneos Health more than 15 years of experience advising companies primarily focused on life sciences and healthcare. He has a broad network in the life sciences private equity community, management consulting, corporate development and transaction advisory work. Mr. Patel has completed regional and cross-border M&A, licensing and financing transactions for biotech and large pharma companies and has more than six years of management consulting experience with clients across several industries to improve their competitive positions through a combination of growth, cost-cutting and asset effectiveness initiatives.
Before joining Syneos Health, Mr. Patel was a member of Burrill & Company’s Merchant Banking Group where he managed strategic transactions for clients through advisory work. Transactions included mergers and acquisitions, partnering/licensing, and financing. Prior to that role, Mr. Patel was a management consultant with AT Kearney and Mercer Management Consulting. His experience includes strategy and operations consulting to international corporate clients in Pharmaceuticals, Biotech, Healthcare, Diagnostics, High Tech and Consumer Goods.